Cargando…
Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
BACKGROUND: Pivotal trials of COVID-19 vaccines did not include cancer patients with questions remaining in this population. Particularly in patients with thoracic malignancies receiving anticancer treatments, the safety of these vaccines has so far been little investigated. METHODS: This is a prosp...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584758/ https://www.ncbi.nlm.nih.gov/pubmed/36372676 http://dx.doi.org/10.1016/j.cllc.2022.10.004 |
_version_ | 1784813343167479808 |
---|---|
author | Spitaleri, G. Trillo Aliaga, P. Catania, C. Signore, E. Del Attili, I. Santoro, C. Giugliano, F. Berton Giachetti, P.P.M Curigliano, G. Passaro, A. de Marinis, F. |
author_facet | Spitaleri, G. Trillo Aliaga, P. Catania, C. Signore, E. Del Attili, I. Santoro, C. Giugliano, F. Berton Giachetti, P.P.M Curigliano, G. Passaro, A. de Marinis, F. |
author_sort | Spitaleri, G. |
collection | PubMed |
description | BACKGROUND: Pivotal trials of COVID-19 vaccines did not include cancer patients with questions remaining in this population. Particularly in patients with thoracic malignancies receiving anticancer treatments, the safety of these vaccines has so far been little investigated. METHODS: This is a prospective trial of patients with thoracic cancer receiving anticancer treatments and COVID-19 vaccines at the Division of Thoracic Oncology of European Institute of Oncology between February and September 2021. RESULTS: A total 207 patients affected by thoracic cancers (199 lung cancers and 8 mesotheliomas) had received Covid-19 vaccines (206 mRNA vaccines and 1 virus-vectored vaccine). The majority of patients had at least one comorbidity (76.3%). They were concomitantly treating with targeted therapy (TT) (45.9%), immunotherapy (IO) (22.7%), and chemotherapy (CT) (14%). A total of 64 AEs (15.6%) were observed after administration of Sars-Cov-2 vaccine. The majority of AEs were grade 1 [G1] (6.3%) and G2 (8.8%), only two events were G3 (0.5%). The median follow-up was 9 months (range 1-22 months), during this follow-up 21 patients (10.1%) had a positive nasal swab, most of the patients were asymptomatic (67%) and the symptomatic ones (33%) had mild symptoms and fewer complications and hospitalizations. CONCLUSIONS: COVID-19 m-RNA vaccines appear to be safe in the cohort of patients with thoracic malignances in active treatment, including those receiving immunotherapy. Considering the high morbidity and mortality associated with COVID-19 in patients with lung cancer receiving active treatments, our study supports the current vaccine prioritization, third and/or fourth dose, of all cancer patients with active treatment. |
format | Online Article Text |
id | pubmed-9584758 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95847582022-10-21 Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers Spitaleri, G. Trillo Aliaga, P. Catania, C. Signore, E. Del Attili, I. Santoro, C. Giugliano, F. Berton Giachetti, P.P.M Curigliano, G. Passaro, A. de Marinis, F. Clin Lung Cancer Original Study BACKGROUND: Pivotal trials of COVID-19 vaccines did not include cancer patients with questions remaining in this population. Particularly in patients with thoracic malignancies receiving anticancer treatments, the safety of these vaccines has so far been little investigated. METHODS: This is a prospective trial of patients with thoracic cancer receiving anticancer treatments and COVID-19 vaccines at the Division of Thoracic Oncology of European Institute of Oncology between February and September 2021. RESULTS: A total 207 patients affected by thoracic cancers (199 lung cancers and 8 mesotheliomas) had received Covid-19 vaccines (206 mRNA vaccines and 1 virus-vectored vaccine). The majority of patients had at least one comorbidity (76.3%). They were concomitantly treating with targeted therapy (TT) (45.9%), immunotherapy (IO) (22.7%), and chemotherapy (CT) (14%). A total of 64 AEs (15.6%) were observed after administration of Sars-Cov-2 vaccine. The majority of AEs were grade 1 [G1] (6.3%) and G2 (8.8%), only two events were G3 (0.5%). The median follow-up was 9 months (range 1-22 months), during this follow-up 21 patients (10.1%) had a positive nasal swab, most of the patients were asymptomatic (67%) and the symptomatic ones (33%) had mild symptoms and fewer complications and hospitalizations. CONCLUSIONS: COVID-19 m-RNA vaccines appear to be safe in the cohort of patients with thoracic malignances in active treatment, including those receiving immunotherapy. Considering the high morbidity and mortality associated with COVID-19 in patients with lung cancer receiving active treatments, our study supports the current vaccine prioritization, third and/or fourth dose, of all cancer patients with active treatment. Elsevier Inc. 2023-01 2022-10-21 /pmc/articles/PMC9584758/ /pubmed/36372676 http://dx.doi.org/10.1016/j.cllc.2022.10.004 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Study Spitaleri, G. Trillo Aliaga, P. Catania, C. Signore, E. Del Attili, I. Santoro, C. Giugliano, F. Berton Giachetti, P.P.M Curigliano, G. Passaro, A. de Marinis, F. Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers |
title | Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers |
title_full | Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers |
title_fullStr | Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers |
title_full_unstemmed | Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers |
title_short | Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers |
title_sort | safety of mrna-covid-19 vaccines in patients with thoracic cancers |
topic | Original Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584758/ https://www.ncbi.nlm.nih.gov/pubmed/36372676 http://dx.doi.org/10.1016/j.cllc.2022.10.004 |
work_keys_str_mv | AT spitalerig safetyofmrnacovid19vaccinesinpatientswiththoraciccancers AT trilloaliagap safetyofmrnacovid19vaccinesinpatientswiththoraciccancers AT cataniac safetyofmrnacovid19vaccinesinpatientswiththoraciccancers AT signoreedel safetyofmrnacovid19vaccinesinpatientswiththoraciccancers AT attilii safetyofmrnacovid19vaccinesinpatientswiththoraciccancers AT santoroc safetyofmrnacovid19vaccinesinpatientswiththoraciccancers AT giuglianof safetyofmrnacovid19vaccinesinpatientswiththoraciccancers AT bertongiachettippm safetyofmrnacovid19vaccinesinpatientswiththoraciccancers AT curiglianog safetyofmrnacovid19vaccinesinpatientswiththoraciccancers AT passaroa safetyofmrnacovid19vaccinesinpatientswiththoraciccancers AT demarinisf safetyofmrnacovid19vaccinesinpatientswiththoraciccancers |